Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
Frankfurt - Delayed Quote EUR

Everest Medicines Limited (6HN.F)

Compare
6.65
+0.20
+(3.10%)
At close: April 4 at 8:02:48 AM GMT+2
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for 6HN.F

Recent News: 6HN.F

View More
Everest Medicines Announces Financial Results for Full Year Ended December 31, 2024

Everest Medicines Announces Financial Results for Full Year Ended December 31, 2024
PR Newswire 11 days ago
Everest Medicines Announces FDA Clearance of IND Application for Tumor-Associated Antigen Vaccine EVM14

Everest Medicines Announces FDA Clearance of IND Application for Tumor-Associated Antigen Vaccine EVM14
PR Newswire 13 days ago
High Growth Tech Stocks in Asia to Watch for Promising Growth

High Growth Tech Stocks in Asia to Watch for Promising Growth
Simply Wall St. 28 days ago
Everest Medicines Announces First Patient Dosed with EVM16, Its First Internally Developed Personalized mRNA Cancer Vaccine

Everest Medicines Announces First Patient Dosed with EVM16, Its First Internally Developed Personalized mRNA Cancer Vaccine
PR Newswire last month
Everest Medicines to Hold Investor Calls with Updates on mRNA Therapeutic Vaccine Programs

Everest Medicines to Hold Investor Calls with Updates on mRNA Therapeutic Vaccine Programs
PR Newswire last month
Everest Medicines Presents Complete Maintenance Period Data for Etrasimod at ECCO 2025

Everest Medicines Presents Complete Maintenance Period Data for Etrasimod at ECCO 2025
PR Newswire last month
Everest Medicines to Announce Full-Year 2024 Financial Results on March 26, 2025

Everest Medicines to Announce Full-Year 2024 Financial Results on March 26, 2025
PR Newswire last month
Everest Medicines Announces the First Prescription of VELSIPITY® in the Greater Bay Area, Officially Benefiting Mainland China Patients

Everest Medicines Announces the First Prescription of VELSIPITY® in the Greater Bay Area, Officially Benefiting Mainland China Patients
PR Newswire 3 months ago
Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY® by the National Medical Products Administration of China for the Treatment of Moderately to Severely Active Ulcerative Colitis

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY® by the National Medical Products Administration of China for the Treatment of Moderately to Severely Active Ulcerative Colitis
PR Newswire 3 months ago
Everest Medicines Announces the First Prescription of VELSIPITY® Issued in Macau, Officially Beginning to Benefit Asian Patients

Everest Medicines Announces the First Prescription of VELSIPITY® Issued in Macau, Officially Beginning to Benefit Asian Patients
PR Newswire 3 months ago
Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy

Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy
PR Newswire 3 months ago
View More

Related Tickers

BOT.AX Botanix Pharmaceuticals Limited
0.4000
-5.88%
 
MSB.AX Mesoblast Limited
1.7650
-5.87%
 
MESO Mesoblast Limited
10.57
-8.88%
 
VERV Verve Therapeutics, Inc.
3.6200
-5.85%
 
NTLA Intellia Therapeutics, Inc.
6.63
-3.77%